Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 2.5% in the first quarter, now owning approximately 10.01% of the company, valued at $3.53 billion.
• CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals, resulting in a 39.26% decrease in her ownership, now holding shares valued at approximately $14.9 million.
• Alnylam Pharmaceuticals recently reported earnings per share of $0.32, beating expectations significantly, with revenue of $773.69 million for the quarter.

Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,056,605 shares of the biopharmaceutical company's stock after buying an additional 323,206 shares during the period. Vanguard Group Inc. owned approximately 10.01% of Alnylam Pharmaceuticals worth $3,525,544,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Whipplewood Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares in the last quarter. Park Square Financial Group LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $28,000. Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $35,000. Finally, Washington Trust Advisors Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 61 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $435.10 on Friday. The company's 50-day moving average is $329.10 and its 200-day moving average is $283.50. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.98. The firm has a market capitalization of $57.03 billion, a PE ratio of -176.15 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $436.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. During the same period in the prior year, the firm earned ($0.13) EPS. The business's revenue was up 17.3% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Jefferies Financial Group increased their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research report on Monday, July 7th. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, UBS Group increased their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Four research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $403.92.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.